
Menu


JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China
July 20, 2020
Shanghai, China and Emeryville, California, July 20, 2020 – JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients
Eureka Therapeutics to Present at Oppenheimer’s Private Life Sciences Company Call Series
June 25, 2020
Emeryville, California, June 25, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced




Eureka Therapeutics Completes $45 Million Series E Financing and Enters into Strategic Collaboration with Lyell Immunopharma
March 17, 2020
Emeryville, California, March 17, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies for solid tumors, today announced that it has
Eureka Therapeutics Announces Upcoming Conference Presentations
March 3, 2020
Emeryville, California, March 3, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced

